PEG-Phospholipid Endothelial Coating for Reperfusion Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Ischemia reperfusion injury (IRI) during organ transplantation leads to thromboinflammation and hemodynamic instability, resulting in graft loss, delayed function, and increased risk of rejection, particularly in marginal organs from deceased-after-cardiac-death donors, where the glycocalyx is damaged and the endothelial surface is unprotected, triggering complement and coagulation system activation.
Innovation Solution
Ex vivo treatment of organs with PEG-phospholipid molecules to form a protective coating on the endothelial lining, inhibiting thromboinflammation by reducing complement and coagulation activation, and preventing hypotension by interacting with cell membranes to mimic the glycocalyx function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ex vivo treatment with PEG-phospholipid molecules is applied to protect endothelial lining, then thromboinflammation is reduced and graft function is improved, but treatment complexity and cost increase
Solution Approach 1:
The patent applies preliminary action by treating the organ with PEG-phospholipid molecules ex vivo before transplantation. This pre-treatment allows the molecules to incorporate into the endothelial cell membranes and form a protective coating in advance, preventing thromboinflammation and complement activation when the organ is reperfused in the recipient, thereby improving graft function while managing treatment complexity through advance preparation
Solution Approach 2:
The PEG-phospholipid molecules serve as an intermediary substance that mediates protection between the endothelial lining and harmful immune responses. These molecules incorporate into cell membranes and act as a protective barrier, preventing direct interaction between damaged endothelial surfaces and complement/coagulation systems, thereby reducing thromboinflammation and improving graft reliability
2Adaptability or versatility
If marginal organs from DCD donors are used to increase donor pool, then organ availability increases, but IRI severity increases due to glycocalyx damage
Solution Approach 1:
The patent converts the harm of glycocalyx damage in marginal organs into a benefit by using PEG-phospholipid molecules that mimic the protective functions of the lost glycocalyx. These molecules compensate for the structural damage already incurred during ischemia, transforming organs that would otherwise be unsuitable for transplantation into viable grafts by preventing subsequent thromboinflammation and complement activation
Solution Approach 2:
The patent applies parameter changes by modifying the surface properties of endothelial cells through incorporation of PEG-phospholipid molecules. This changes the physical and chemical parameters of the cell surface, creating a protective interface that prevents harmful interactions between damaged endothelium and the recipient's immune system, thereby enabling use of marginal organs with improved outcomes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly reduces thromboinflammation markers, suppresses cytokine expression, improves graft function, and prevents hypotension, thereby enhancing transplant success and reducing the risk of graft loss and rejection.
Implementation Method 1
The amphiphilic polymer polyethylene glycol)-phospholipid (PEG-conjugated phospholipid or simply PEG-phospholipid) is spontaneously incorporated into the lipid bilayer membrane of cell membranes by hydrophobic interactions
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
An organ graft is ex vivo treated by ex vivo infusing a solution comprising PEG-phospholipid molecules into a vascular system of the organ graft. The solution comprising PEG-phospholipid molecules is ex vivo incubated in the vascular system to enable coating of at least a portion of the endothelial lining of the vascular system with the PEG-phospholipid molecules while keeping the organ or the part of the organ submerged in an organ preservation solution comprising PEG-phospholipid molecules. Such an ex vivo treatment of organ grafts with PEG-phospholipid protected the organ grafts against thromboinflammationand reduced blood pressure drops that otherwise occurred when reperfusing the organ graft in the recipient.